A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.

Slides:



Advertisements
Similar presentations
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Advertisements

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
Goede V et al. Proc ASCO 2013;Abstract 7004.
1Coiffier B et al. Proc ASH 2010;Abstract 114.
Robertson JFR et al. J Clin Oncol 2009;27(27):
Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.
AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.
First Safety Data from a Randomized Phase III (CIBOMA/ /GEICAM ) Trial Assessing Adjuvant Capecitabine Maintenance Therapy After Standard.
A Phase III study (EMBRACE. ) of eribulin mesylate vs
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
A Phase III Study (EMBRACE) of Eribulin Mesylate versus Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer.
Locally advanced and metastatic disease
E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
Pritchard KI et al. Proc SABCS 2010;Abstract P
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
1 Flinn I et al. Proc ICML 2013;Abstract 084.
Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
CCO Independent Conference Coverage
Slamon D et al. SABCS 2009;Abstract 62.
Alessandra Gennari, MD PhD
Palumbo A et al. Proc ASH 2012;Abstract 200.
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
Gajria D et al. Proc SABCS 2010;Abstract P
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.
Vahdat L et al. Proc SABCS 2012;Abstract P
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Swain SM et al. Proc SABCS 2012;Abstract P
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Barrios C et al. SABCS 2009;Abstract 46.
Krop I et al. SABCS 2009;Abstract 5090.
Coiffier B et al. Proc ASH 2010;Abstract 857.
Baselga J et al. SABCS 2009;Abstract 45.
Martin M et al. Proc SABCS 2012;Abstract S1-7.
Presentation transcript:

A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes Kaufman PA et al. Proc SABCS 2012;Abstract S6-6.

Background The Phase III EMBRACE trial demonstrated a significant 2.5-month survival advantage with eribulin versus treatment of physician's choice for patients with locally recurrent or metastatic breast cancer (mBC) who previously received ≥2 chemotherapeutic regimens for advanced BC (Lancet 2011;377:914). Capecitabine is a widely used agent for the treatment of first-, second- and third-line mBC and is approved for mBC that is resistant to paclitaxel and an anthracycline-based regimen. Study objective: To compare the efficacy and safety of eribulin to capecitabine for patients with locally advanced or mBC previously treated with anthracyclines and taxanes. Kaufman PA et al. Proc SABCS 2012;Abstract S6-6.

Phase III Study 301 Design Eligibility (n = 1,102) Locally advanced or mBC ≤3 prior chemotherapy regimens (≤2 for advanced Dx) Prior taxane and anthracycline in (neo)adjuvant setting or for locally advanced or mBC Coprimary endpoints: Overall survival (OS) and progression-free survival (PFS) Secondary endpoints include: Quality of life, overall response rate (ORR), duration of response and safety Patients were stratified according to geographical region and HER2 status. Eribulin (n = 554) 1.4 mg/m 2 for 2-5 min (IV)* d1, 8, q21d Capecitabine (n = 548) 1,250 mg/m 2 BID (oral) d1-14, q21d Kaufman PA et al. Proc SABCS 2012;Abstract S6-6. * Equivalent to 1.23 mg/m 2 of eribulin R

Statistical Considerations for Coprimary Endpoints Primary predefined analyses for ITT population –2-sided log-rank test, stratified for HER2 and geographic region –Hazard ratio (HR) based on Cox regression model Planned for enrollment (n = 1,100) –OS determination: 905 events –Final analysis: 82% of events –Sufficient for 90% probability if HR ≤0.8 (Type I error: 0.04) 2 planned interim analyses of OS by O’Brien-Fleming spending function: 453 and 603 deaths Final analysis would be positive vs capecitabine if either: –OS is significantly improved with eribulin (p ≤ ) –PFS by independent review is significantly prolonged with eribulin (p ≤ 0.01); HR for OS (eribulin/capecitabine) is <1 Kaufman PA et al. Proc SABCS 2012;Abstract S6-6.

Coprimary Endpoints: OS and PFS Outcome Eribulin (n = 554) Cape (n = 548) Hazard ratiop-value Median OS15.9 mo14.5 mo year OS64.4%58.0%NR year OS32.8% 29.8%NR year OS17.8%14.5%NR0.175 Median PFS Independent review Investigator review 4.1 mo 4.2 mo 4.1 mo Cape = capecitabine; NR = not reported Kaufman PA et al. Proc SABCS 2012;Abstract S6-6.

OS: Prespecified Subgroup Analysis Median OS EribulinCapeHazard ratio HER2 status Positive Negative 14.3 mo 15.9 mo 17.1 mo 13.5 mo ER status Positive Negative 18.2 mo 14.4 mo 16.8 mo 10.5 mo Triple-negative BC (TNBC) Yes No 14.4 mo 17.5 mo 9.4 mo 16.6 mo Overall15.9 mo14.5 mo0.879 Hazard ratio <1.0 favors eribulin Kaufman PA et al. Proc SABCS 2012;Abstract S6-6.

Response Rates Response Independent reviewInvestigator review Eribulin (n = 554) Cape (n = 548) Eribulin (n = 554) Cape (n = 548) ORR 11%12%16%20% p-value = p-value = SD57%55%60%51% PD23% 24%18%23% NE2%1%6% Unknown8% 0% Unconfirmed CR/PR— —4%3% CBR26% 27%33%34% ORR = objective response rate; SD = stable disease; PD = progressive disease; NE = not evaluated; CR = complete response; PR = partial response; CBR = clinical benefit rate Kaufman PA et al. Proc SABCS 2012;Abstract S6-6.

Select Adverse Events (Incidence >10%, All Grades; 1%, Grade 3/4) Grade Eribulin (n = 544)Cape (n = 546) All3/4All3/4 Neutropenia54%46%16%<5% Leukopenia31%15%10%<3% Febrile neutropenia2% <3%<1%<2% Hand-foot syndrome<1%0%45%14% Alopecia35% —4%— Diarrhea14% 1%29%<6% Vomiting12% <2%17%2% Peripheral sensory neuropathy13% 4%7%<1% Dyspnea*10% <3%11%<4% * Grade 5 events occurred in 0.7% (eribulin) and 0.5% (cape) Kaufman PA et al. Proc SABCS 2012;Abstract S6-6.

Author Conclusions This trial did not demonstrate a statistically significant superiority of eribulin to capecitabine in either OS or PFS. –Median OS: 15.9 mo (eribulin), 14.5 mo (cape); HR: Prespecified exploratory analyses suggested that particular patient subgroups may have greater therapeutic benefit with eribulin and this may warrant further study. –TNBC (HR: 0.702) –ER-negative (HR: 0.779) –HER2-negative (HR: 0.838) Eribulin and capecitabine demonstrated similar overall activity in this study, which included patients in the first-, second- or third-line treatment setting. The toxicity profiles of eribulin and capecitabine were consistent with previously known side effects. Kaufman PA et al. Proc SABCS 2012;Abstract S6-6.

Investigator Commentary: A Phase III Trial Comparing Eribulin to Capecitabine for Previously Treated Locally Advanced or mBC In my practice, I’m impressed with eribulin activity. After its approval, I have administered it to patients with heavily pretreated BC. For instance, a patient with PD on every other agent was started on eribulin 9 weeks ago, and her liver lesions have already reduced in size by 50%. Unfortunately, there are no biomarkers to predict response. It was disappointing to discover that eribulin was not superior to capecitabine because it’s always good to have a drug that’s better than one that’s been available for a decade. Interview with Kimberly L Blackwell, MD, January 8, 2013 This is an important trial for clinical practice. Both eribulin and capecitabine are FDA approved for refractory mBC. This trial showed that eribulin was fairly equivalent to capecitabine in terms of efficacy. Some may view it as a negative study because it failed to demonstrate that eribulin was better than capecitabine. However, I view it as a positive trial showing that there are available options for patients with mBC. The toxic effects for both agents were manageable. Interestingly, in the prespecified subset analysis of patients with TNBC, ER-negative or HER2-negative BC, it appeared that eribulin may offer an advantage over capecitabine. These data support the ongoing evaluation of eribulin in a subset of patients with TNBC. Interview with Edith A Perez, MD, January 17, 2013